Who are Magnesium Sulfate high dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, DXM + Propofol, Ketamine and Midazolam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/magnesium-sulfate-high-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Magnesium Sulfate high dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnesium Sulfate high dose (Magnesium Sulfate high dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist / Anticonvulsant. Area: Neurology.

phase 3 NMDA receptor antagonist / Anticonvulsant NMDA receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Magnesium Sulfate high dose (Magnesium Sulfate high dose) — Dr Olu Bamgbade, MD, FRCPC. High-dose magnesium sulfate acts as a NMDA receptor antagonist and stabilizes neuronal membranes, reducing excitotoxicity and seizure activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Magnesium Sulfate high dose TARGET	Magnesium Sulfate high dose	Dr Olu Bamgbade, MD, FRCPC	phase 3	NMDA receptor antagonist / Anticonvulsant	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
DXM + Propofol	DXM + Propofol	Seoul National University Hospital	marketed	Dissociative anesthetic combination	NMDA receptor (DXM); GABA-A receptor (propofol)
Ketamine and Midazolam	Ketamine and Midazolam	Kanuni Sultan Suleyman Training and Research Hospital	marketed	Dissociative anesthetic and benzodiazepine combination	NMDA receptor (ketamine); GABA-A receptor (midazolam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist / Anticonvulsant class)

Dr Olu Bamgbade, MD, FRCPC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Magnesium Sulfate high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/magnesium-sulfate-high-dose. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab